
Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Luke Laffin, MD, discusses his secondary analysis of the phase 2 KARDINAL trial, which demonstrated substantial improvements in uncontrolled hypertension.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

September 14th 2026